English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Pneumocystis  pneumonia (PcP), which is caused by  Pneumocystis carinii,  is a life-threatening infection that affects immunocompromised individuals. Unfortunately, chemoprophylaxis and dapsone are only effective for half of the patients with PcP, indicating that additional preventive methods are needed. We predicated the  pneumocystis  surface protein A12 sequence 1–85 by DNAStar software and BepiPred, and identified it as a potential vaccine candidate by bioresearch.    Methods  We used recombinant A12 1–85  as antigen to immunized mice and detected serum titer of IgG, expression of inflammatory factors by EILSA, qRT-PCR and flow cytometry.    Results  Our results showed that immunization with recombinant A12 1–85  increased the serum titer of IgG, promoted the secretion of T lymphocytes, increased the expression of inflammatory factors, and elevated lung inflammatory injury in mice.    Conclusions  Our findings suggest that A12 1–85  is a potential vaccine target for preventing  Pneumocystis carinii . The evaluation of A12 1–85 -elicited antibodies in the prevention of PcP in humans deserves further investigation.    Supplementary Information  The online version contains supplementary material available at 10.1186/s12865-021-00436-6.

Immunization with Pneumocystis carinii A121–85 antigen activates immune function against P. carinii